Lisata Therapeutics, Inc. LSTA
1.58
0.08
5.33%
as of 25 Sep
- Market cap
- $13.5M
- P/E
- 0.0×
Follow LSTA
Growth Flags
show if company had growth for consecutive years
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
— | — | — | — | — | — | — | — | 0.00 | 0.00 |
P/S ratio |
— | — | — | — | — | — | — | — | 0.93 | 1.06 |
P/FCF ratio |
— | — | — | — | — | — | — | — | 0.00 | 0.00 |
P/Operating CF |
— | — | — | — | — | — | — | — | (5.48) | (4.97) |
P/B ratio |
— | — | — | — | — | — | — | — | 0.85 | 1.11 |
Price to Tangible BV |
— | — | — | — | — | — | — | — | 0.85 | 1.12 |
EV/Sales |
— | — | — | — | — | — | — | — | (0.23) | 0.04 |
EV/EBITDA |
— | — | — | — | — | — | — | — | 0.26 | 0.00 |
EV/Operating CF |
— | — | — | — | — | — | — | — | 0.31 | (0.03) |
EV/FCF |
— | — | — | — | — | — | — | — | 0.31 | (0.03) |
Quick Ratio |
0.34 | 6.45 | 7.66 | 4.21 | 9.86 | 21.00 | 10.85 | 7.67 | 5.73 | 5.20 |
Current Ratio |
1.16 | 6.59 | 7.85 | 4.35 | 10.08 | 21.27 | 11.26 | 8.18 | 6.16 | 5.76 |
Net Debt/EBITDA |
0.04 | 2.23 | 2.61 | 1.22 | 1.81 | 3.56 | 1.21 | 1.91 | 1.38 | 0.88 |
Debt/Assets |
10.86% | 0.25% | 0.00% | 3.60% | 1.73% | 0.74% | 0.66% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
1.43 | 0.00 | 0.00 | 0.05 | 0.02 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.01 |
Operating CF/Net income |
0.72 | (0.91) | 1.24 | 0.98 | 1.08 | 0.81 | 0.39 | 0.96 | 0.97 | 0.96 |
Capex/Depreciation |
(2.44) | (0.19) | (0.26) | 0.00 | (0.05) | (0.02) | (0.33) | 0.00 | 0.00 | (0.39) |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| (238.80%) | 84.71% | (36.89%) | (66.75%) | (30.87%) | (44.21%) | (68.50%) | (36.49%) | (51.77%) | (75.53%) | |
| (58.99%) | 39.32% | (29.95%) | (53.98%) | (25.81%) | (41.30%) | (63.78%) | (32.63%) | (44.56%) | (62.89%) | |
ROIC |
(658.43%) | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(782.84%) | 43.90% | (41.83%) | (96.34%) | (25.56%) | (29.95%) | (82.42%) | (43.87%) | (68.83%) | (113.22%) |
Average Days of Receivables |
0.00 | — | — | — | — | — | — | — | 328.50 | 0.00 |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 1,133.40% | 4,675.88% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 1,207.50% | 6,135.29% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 165.30% | 721.18% |
Graham Net Nets |
— | — | — | — | — | — | — | — | 1.16 | 0.90 |
Graham Number |
— | — | — | — | — | — | — | — | 0.00 | 0.00 |
Earnings Yield |
— | — | — | — | — | — | — | — | (80.54%) | (102.69%) |
Free Cash Flow Yield |
— | — | — | — | — | — | — | — | (79.13%) | (98.88%) |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.12 | 0.02 |
Operating CF per Share |
(54.18) | (34.90) | (30.92) | (27.42) | (8.57) | (6.03) | (4.09) | (2.48) | (2.32) | (1.84) |
Capex per Share |
(2.52) | (0.23) | (0.21) | 0.00 | (0.02) | (0.02) | (0.05) | 0.00 | 0.00 | 0.00 |
Free Cash Flow per Share |
(56.70) | (35.12) | (31.13) | (27.42) | (8.59) | (6.05) | (4.14) | (2.48) | (2.32) | (1.84) |
Cash per Share |
16.20 | 100.44 | 66.61 | 36.53 | 33.57 | 25.75 | 13.36 | 6.26 | 3.75 | 1.84 |
Shareholders Equity per Share |
9.31 | 83.90 | 57.95 | 29.84 | 31.31 | 24.95 | 12.80 | 5.93 | 3.52 | 1.68 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
9.31 | 83.90 | 57.95 | 29.84 | 31.31 | 24.95 | 12.80 | 5.93 | 3.52 | 1.68 |
Free Cash Flow |
(24.77) | (21.01) | (20.12) | (18.88) | (8.84) | (22.30) | (21.45) | (20.03) | (19.36) | (15.98) |
Working Capital |
3.47 | 52.08 | 38.49 | 20.00 | 31.83 | 91.66 | 65.49 | 47.33 | 28.97 | 14.63 |
Capital Expenditures |
(1.10) | (0.13) | (0.13) | — | (0.02) | (0.06) | (0.28) | — | — | (0.03) |
Net Current Asset Value |
(24.80) | 48.21 | 36.98 | 19.37 | 31.57 | 91.17 | 65.17 | 47.12 | 28.89 | 14.56 |
EV/EBIT |
— | — | — | — | — | — | — | — | 0.27 | 0.00 |
Capex to Sales |
0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.16 |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | (1,998.50%) | (9,756.47%) |
Price to Operating Income |
— | — | — | — | — | — | — | — | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.64 | 2.77 | 3.07 | 2.97 | 6.49 | 41.44 | 2.90 | (4.41) | (3.90) | 3.94 |
Cash ROIC |
(143.76%) | (19.14%) | (25.03%) | (40.66%) | (13.17%) | (11.89%) | (15.78%) | (20.53%) | (32.08%) | (52.25%) |
Accounts Receivable Turnover |
0.00 | — | — | — | — | — | — | — | 1.93 | 0.00 |
Accounts Payable Turnover |
0.14 | 0.21 | 0.21 | 0.06 | 0.05 | 0.04 | 0.03 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
1,804.82 | 1,317.73 | 1,236.13 | 8,366.92 | 5,909.52 | 12,834.73 | 14,044.57 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Average Receivables |
1.35 | — | — | — | — | — | — | — | 0.52 | — |
Average Payables |
3.17 | 1.78 | 1.05 | 1.13 | 1.26 | 1.48 | 2.29 | 2.54 | 1.85 | 1.15 |
Average Assets |
55.36 | 58.45 | 53.98 | 35.87 | 31.58 | 66.51 | 85.02 | 63.86 | 44.85 | 26.37 |
Average Common Equity |
13.68 | 27.13 | 43.82 | 29.00 | 26.40 | 62.12 | 79.16 | 57.11 | 38.61 | 21.96 |
Columns are period end dates